Mr. deGoa was CEO of RareGen, LLC, a rare disease commercial company until its merger with Liquidia.  Previously, Mr. deGoa was CEO of Breas Medical Group, a global respiratory medical device company, headquartered in Sweden, until its sale to Fosun Pharma.  Since 2012, Mr. deGoa was a Managing Director/Partner at PBM Capital Group, a healthcare investment firm where he was responsible for M&A and executive leadership at portfolio companies like RareGen and Breas.  Mr. deGoa started his career in the healthcare industry with Perrigo Company holding various roles including corporate development, international business development, and divisional finance lead.

Mr. deGoa holds a BA from the University of Michigan and a MBA from Depaul University.

Mr. Kaseta joined Liquidia in December 2020 with an extensive background in corporate finance, business strategy and the commercialization of biopharma products. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, Mr. Kaseta served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent eleven years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and over one hundred products across eight therapeutic areas. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.

Mr. Lippe is responsible for all aspects of operations at Liquidia, including manufacturing, supply chain management, quality, facilities, and program management. Prior to joining Liquidia in 2015, Mr. Lippe served as an Executive Vice President of Operations and Chief Operations Officer at Alexza Pharmaceuticals. In these roles, he had operational oversight for the scale-up and optimization of supply that supported the launch of the company’s first commercial product, and he advanced a platform proof-of-concept which accelerated the company’s product pipeline. He also worked as the Head of Global Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc., and as the Head of Manufacturing for one of Genentech’s Vacaville operating facilities. Mr. Lippe spent 10 years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard. He received his MPH and MBA degrees from the University of California, Berkeley, and received a B.S. degree in Marine Engineering from the United States Coast Guard Academy.

Dr. Shah joined Liquidia in May 2020 and oversees all aspects of research, clinical development, medical affairs, and regulatory affairs for the company. Prior to Liquidia, Dr. Shah served as Head of Global Specialty Clinical Development at Teva Pharmaceuticals with oversight of all phases of clinical development across all therapeutic areas including CNS, immunology, respiratory, oncology and biosimilars. Prior to Teva, Dr. Shah served as Senior Vice President, Scientific and Clinical Development at Altana Pharma US, where he built and led their clinical development function, including clinical research and operations, medical affairs, regulatory affairs and quality assurance, pharmacovigilance and drug safety, biostatistics and data management. He began his career at GlaxoSmithKline (GSK), where he held roles of increasing responsibility and most recently served as U.S. Head, Respiratory and Inflammation, Discovery Medicine and Clinical Pharmacology responsible for early-stage clinical development of new therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and rhinitis. Dr. Shah received a M.D. degree from the Hershey Medical College at Pennsylvania State University. He completed his residency in Internal Medicine at the University of North Carolina and fellowship in Allergy, Asthma and Clinical Immunology at Johns Hopkins University.

Mr. Moomaw joined Liquidia in November 2020 from RareGen where he held the position of Chief Operations Officer (COO) since August 2018. Mr. Moomaw is a seasoned leader in biopharmaceuticals with extensive experience launching products and developing commercial strategies and sales organizations. At RareGen he co-founded the company, built the organization, and launched Treprostinil for PAH. Prior to RareGen Mr. Moomaw was Vice President of Marketing at Opko Health. As Vice President of Marketing for United Therapeutics he had responsibility for Remodulin (parenteral Treprostinil), Tyvaso (inhaled Treprostinil), and Orenitram (oral Treprostinil) for PAH. Mr. Moomaw also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over ten years. Mr. Moomaw holds his MBA from the University of Michigan and a Bachelor of Science (B.S.) from Miami University.

As Vice President, Corporate Development & Strategy at Liquidia, Mr. Adair is responsible for pursuing collaboration and licensing opportunities for the company. Prior to joining Liquidia in 2016, Mr. Adair led business development efforts at BioCryst Pharmaceuticals as their Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company’s first FDA approved drug. He also worked at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Mr. Adair worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He received an MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemistry from Wake Forest University.